Zhengye Biotechnology Holding Limited Announces Implementation of Dual-Class Share Structure
Rhea-AI Summary
Zhengye Biotechnology (Nasdaq: ZYBT) implemented a dual-class share structure effective April 7, 2026, following shareholder approval on March 24, 2026.
The authorized capital was reclassified to 2,000,000,000 ordinary shares (1,900,000,000 Class A; 100,000,000 Class B). Class A carries one vote; Class B carries twenty votes and is convertible into Class A at holder option. Amended governance documents were filed and are effective.
Positive
- Class A shares continue trading under ticker ZYBT
- Adopted amended articles and memorandum now filed and effective
- Class B conversion gives holders optional liquidity via conversion to Class A
Negative
- Class B shares carry 20 votes per share, concentrating voting power
- Class A shares are non-convertible into Class B, limiting vote mobility
- Authorized share capital reclassified to 2,000,000,000 shares, changing capital structure
News Market Reaction – ZYBT
In the Apr 6 session, ZYBT gained 1.23%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 10 | Chairman’s letter update | Positive | -2.9% | Outlined 2025 milestones and 2026 strategic priorities across R&D and commercialization. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
The last notable corporate update with strategic milestones saw a negative price reaction despite constructive content.
In the past six months, Zhengye highlighted listing progress and operational milestones. A Feb 10, 2026 chairman’s letter detailed 4 patent grants, 10 patent filings, multiple veterinary drug approvals, and international expansion efforts. Despite these achievements, the stock fell 2.86% the next day. Today’s dual-class share implementation continues that focus on long-term structure and strategy rather than near-term financial results.
Key Terms
cusip financial
par value financial
memorandum and articles of association regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Jilin, China, April 06, 2026 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the “Company” or “Zhengye”), a veterinary vaccine manufacturer that encompasses research, development, manufacturing, and sales of veterinary vaccines, with a focus on livestock vaccines in China, today announced the implementation of a dual-class share structure, effective April 7, 2026.
At the annual general meeting of shareholders held on March 24, 2026, the Company’s shareholders approved the introduction of two classes of ordinary shares, designated as Class A and Class B. The Company’s Class A ordinary shares are expected to begin trading on the Nasdaq Capital Market at the open of business on April 7, 2026, continuing under the ticker symbol “ZYBT.” While the CUSIP number will remain the same, the CUSIP description will be updated to reflect the new designation as Class A ordinary shares.
Pursuant to the dual-class share structure, the Company’s authorized share capital of US
To reflect the share capital reorganization, Zhengye has adopted amended and restated memorandum and articles of association, which have been duly filed and are now effective.
About Zhengye Biotechnology Holding Limited
Through Jilin Zhengye Biological Products Co., Ltd., the Company’s operating entity based in Jilin, China, Zhengye Biotechnology Holding Limited focuses on the research, development, manufacturing, and sales of veterinary vaccines, with an emphasis on vaccines for livestock. For over 20 years, the operating entity has been committed to enhancing the health of animals. The operating entity has 50 veterinary vaccines, including vaccines for swine, cattle, goats, sheep, poultry, and dogs. The operating entity’s products are available in 28 provincial regions across China and are exported overseas to Vietnam, Pakistan, and Egypt. The operating entity has three GMP veterinary vaccine production floors (including 13 GMP vaccine production lines), one quality examination center, and one animal facility for vaccine development. The operating entity has 49 employees who have over a decade of tenure and experience in the veterinary vaccine industry. For more information, please visit the Company’s website: http://ir.jlzybio.com.
Forward-Looking Statements
This announcement contains statements that may constitute “forward-looking” statements which are made pursuant to the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy, and financial needs. Investors can find many (but not all) of these statements by the use of words such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions in this announcement. Statements that are not historical facts, including statements about the Company’s beliefs, plans, and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and other filings with the United States Securities and Exchange Commission.
For more information, please contact:
Zhengye Biotechnology Holding Limited
Investor Relations Department
Email: ir@jlzybio.com
Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email: investors@ascent-ir.com
